Health 2.0 announces keynotes and preliminary program

11 - 12 May 2016, Barcelona, Spain.
Health 2.0 announces keynote speakers and preliminary program for the 7th Annual Health 2.0 Europe Conference. After a highly successful conference last May in Barcelona, the International event series will be back for another 3 full days discussing challenges faced by the healthcare system and showcasing the latest technologies and innovations that are making an impact.

Health 2.0 Europe is a truly international conference, bringing speakers from all across the world to discuss and find solutions to those healthcare challenges from a global perspective. It will bring together 600 digital health champions including entrepreneurs, executives, thoughtleaders, investors, physicians, and patients over insightful keynotes, interactive workshops, animated round tables and more than 50 rapid fire live demo.

The keynote speakers already confirmed are:

  • Esther Dyson, active business angel and board member in various healthcare companies, she was named by Forbes as one of the most powerful American business woman. She will share her vision on the healthcare challenges and how to tackle them.
  • Dr. Rafael Grossmann, the surgeon who practiced the 1 st live surgery using Google Glass will showcase exclusive innovative solutions he is using and that are supporting both healthcare professionals and enhancing patients' experience.
  • Damien Marmion, Global Head of Health at AXA, will share AXA’s vision as an insurance pioneer in reimbursing digital health solutions and the role of reimbursement in accelerating adoption of digital health in Europe.
  • Dr. Julio Mayol, chief medical and innovation officer at San Carlos Hospital in Madrid, will give his vision on how hospitals should look at health 2.0 solutions and present their successful Smart Health Lab, an initiative launched to design, develop and implement innovative solutions.
  • Pēteris Zilgalvis, Head of Unit for eHealth and Well Being in DG CONNECT, will share the vision and strategic plan of the European Commission on getting a more dynamic digital health ecosystem, involving every stakeholder.

Health 2.0 Europe takes into account all the different stakeholders of the digital health ecosystem. Some of the topics that we will be discussing this year:

  • Solutions for hospitals and healthcare professionals
  • Building a new framework for Health 2.0 adoption in the clinic setting
  • Building Blocks to a Dynamic Health 2.0 Ecosystem in Europe
  • Health 2.0 Applications in Emerging Markets
  • Data Analytics: Structuring Information for DecisionMaking
  • Choosing your Digital Health Accelerator
  • Pharma 2.0: Going Beyond the Pill
  • Frontiers of Health 2.0: What's Next?
  • Power to the patient
  • Technology promoting behaviour change and healthy
  • Health 2.0 transforming the daily mission of nurses
  • Who will pay for Health 2.0? An investor's discussion
  • Reimbursement players, trends, criteria and processes
  • SHUSH topics and the famous unmentionables
  • From Health to WellBeing: the rise of wearables and consumer interfaces

For further information and to register, please visit:
https://goo.gl/IVCb3P

Early bird prices end on 18th March. Book you ticket now using the code EHNEWS16 to get 15% discount.

About Health 2.0
Health 2.0 is the premiere showcase and catalyst for the advancement of new health technologies. Through a global series of conferences, developer competitions, and leading market intelligence, Health 2.0 drives the innovation and collaboration necessary to transform health and health care. In addition to our flagship event held in the Bay Area each Fall, we host events around the world including in Europe, Latin America and India, and new for 2015 Korea and Japan.

Most Popular Now

Pfizer begins a Phase 1/2 study to evaluate respir…

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV i...

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Spiolto® Respimat® enables greater physical activi…

Boehringer Ingelheim announced data which add to the growing body of evidence that show Spiolto® (tiotropium/olodaterol) Respimat® enables greater physical activity in pa...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study demonstrates new treatment for severe asthma

Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering ...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...